Biogen (BIIB) PT Raised to $309 at Baird on Additional Sola Details
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Biogen Presents Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab at 2016 Clinical Trials on Alzheimer’s Disease Meeting
December 8, 2016 6:16 PM ESTData Includes Analyses of Phase 1b Titration Cohort and Long-Term Extension Cohort
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen (NASDAQ: BIIB) announced it will present new data from the Phase 1b (PRIME) study of aducanumab, its investigational treatment for early Alzheimers disease (AD), today at the 9th Clinical Trials on Alzheimer's Disease (CTAD) meeting in San Diego.... More
